par Tanaka, Tetsuya;Legat, Amandine
;Adam, Emmanuelle
;Steuve, Jonathan
;Gatot, Jean-Stéphane
;Vandenbranden, Michel
;Ulianov, Liliana;Lonez, Caroline
;Ruysschaert, Jean Marie
;Muraille, Eric
;Tuynder, Marcel;Goldman, Michel
;Jacquet, Alain 
Référence European Journal of Immunology, 38, 5, page (1351-1357)
Publication Publié, 2008-05










Référence European Journal of Immunology, 38, 5, page (1351-1357)
Publication Publié, 2008-05
Article révisé par les pairs
Résumé : | DiC14-amidine cationic liposomes were recently shown to promote Th1 responses when mixed with allergen. To further define the mode of action of diC14-amidine as potential vaccine adjuvant, we characterized its effects on mouse and human myeloid dendritic cells (DC). First, we observed that, as compared with two other cationic liposomes, only diC14-amidine liposomes induced the production of IL-12p40 and TNF-alpha by mouse bone marrow-derived DC. DiC14-amidine liposomes also activated human DC, as shown by synthesis of IL-12p40 and TNF-alpha, accumulation of IL-6, IFN-beta and CXCL10 mRNA, and up-regulation of membrane expression of CD80 and CD86. DC stimulation by diC14-amidine liposomes was associated with activation of NF-kappaB, ERK1/2, JNK and p38 MAP kinases. Finally, we demonstrated in mouse and human cells that diC14-amidine liposomes use Toll-like receptor 4 to elicit both MyD88-dependent and Toll/IL-1R-containing adaptor inducing interferon IFN-beta (TRIF)-dependent responses. |